Newsfeeds - Spark Newswire

1 minute read

Nektar Therapeutics Q3 EPS $(0.31) Beats $(0.45) Estimate, Sales $23.63M Beat $22.61M Estimate

Today, 10:37 PM

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.45) by 31.11 percent. This is a 55.71 percent increase over losses of $(0.70) per share

NKTR

31 minute read

Earnings

Earnings Scheduled For November 3, 2022

By Benzinga Insights

Today, 10:37 PM

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.

AAOI

1 minute read

M&A
News

Nektar Announced That It Has Mutually Agreed With Puretech to Terminate Discussions Regarding a Potential Business Combination

By Charles Gross

Today, 10:37 PM

Further to the announcement made by PureTech Health plc ("PureTech") on 7 October 2022, Nektar announces that it has mutually agreed with PureTech to terminate discussions regarding a potential business combination.

NKTR

1 minute read

PureTech Health Confirms ‘Possible’ Merger With Nektar Therapeutics

By Vandana Singh

Today, 10:37 PM

PureTech Health plc (NASDAQ:PRTC) has confirmed that it is in talks about a possible tie-up with Nektar Therapeutics (NASDAQ:NKTR). In April, Nektar Therapeutics…

BMY

1 minute read

M&A
News

Puretech Health Confirmed That It Has Exchanged Indicative, Non-binding Proposals With Nektar Therapeutics Regarding a Possible Combination

By Charles Gross

Today, 10:37 PM

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") notes the recent press speculation and confirms that it has exchanged indicative, non-binding proposals with Nektar Therapeutics, Inc. ("Nektar") regarding a possible combination (which may include, amongst other things, an offer for share capital of PureTech) (the "Proposal").

NKTR

2 minute read

Earnings

Nektar Therapeutics’s Return On Capital Employed Insights

By Benzinga Insights

Today, 10:37 PM

Nektar Therapeutics (NASDAQ:NKTR) brought in sales totaling $21.59 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 75.97%, resulting in a loss of $159.07 million.

NKTR

2 minute read

Nektar And Collaborators Announce Preclinical Publication Of Data For NKTR-255 And Its Observed Improvement Of NK Cell Function In Multiple Myeloma

By Benzinga Newsdesk

Today, 10:37 PM

Nektar Therapeutics (NASDAQ:NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society of Hematology, highlighting the effects of NKTR-255, a novel

NKTR